Otonomy, Inc, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase I/II clinical trial to treat tinnitus; and OTO-413, a proprietary formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone619-323-2200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$750,000.00
Profitability
Miscellaneous
Employees49
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Otonomy (NASDAQ:OTIC) Frequently Asked Questions
What is Otonomy's stock symbol?
Otonomy trades on the NASDAQ under the ticker symbol "OTIC."
How were Otonomy's earnings last quarter?
Otonomy Inc (NASDAQ:OTIC) issued its quarterly earnings results on Thursday, August, 1st. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.48) by $0.10. The biopharmaceutical company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.50 million. Otonomy had a negative net margin of 6,984.64% and a negative return on equity of 65.91%. View Otonomy's Earnings History.
When is Otonomy's next earnings date?
What price target have analysts set for OTIC?
3 equities research analysts have issued twelve-month price objectives for Otonomy's shares. Their predictions range from $5.00 to $8.00. On average, they anticipate Otonomy's stock price to reach $6.50 in the next twelve months. This suggests a possible upside of 191.5% from the stock's current price. View Analyst Price Targets for Otonomy.
What is the consensus analysts' recommendation for Otonomy?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Otonomy.
What are Wall Street analysts saying about Otonomy stock?
Here are some recent quotes from research analysts about Otonomy stock:
- 1. According to Zacks Investment Research, "Otonomy, Inc. engages in developing and commercializing therapeutics to address unmet medical needs in the otology market. It develops therapeutics for treatment of inner and middle ear disorders. The Company's product candidates under development includes AuriPro to treat pediatric patients with middle ear effusion; and OTO-104 for the treatment of patients with Ménière's disease. Otonomy, Inc. is headquartered in San Diego, California. " (10/17/2019)
- 2. HC Wainwright analysts commented, "Our $8 12-month target is based on a 60% probability of success adjusted DCF. We only include in our model—assuming 2022 launch and over $300M peak sales—and do not include any contribution from the early-stage pipeline. Our DCF reflects a 12% WACC discount rate and 1% terminal growth beyond 2028, which we think is appropriate assuming IP into the 2030s, and a likely high generic bioequivalence bar for locally acting therapy, requiring a head-to-head clinical trial." (8/29/2019)
Has Otonomy been receiving favorable news coverage?
News coverage about OTIC stock has trended somewhat negative on Wednesday, according to InfoTrie. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Otonomy earned a daily sentiment score of -1.3 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Otonomy.
Are investors shorting Otonomy?
Otonomy saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 132,400 shares, an increase of 46.8% from the August 30th total of 90,200 shares. Based on an average daily volume of 47,600 shares, the short-interest ratio is presently 2.8 days. Currently, 0.5% of the company's shares are sold short. View Otonomy's Current Options Chain.
Who are some of Otonomy's key competitors?
Some companies that are related to Otonomy include Forty Seven (FTSV), Applied Therapeutics (APLT), BIOFRONTERA AG/ADR (BFRA), MannKind (MNKD), resTORbio (TORC), Syros Pharmaceuticals (SYRS), Seres Therapeutics (MCRB), Mallinckrodt (MNK), Provention Bio (PRVB), Stealth BioTherapeutics (MITO), Xenon Pharmaceuticals (XENE), Evofem Biosciences (EVFM), Galectin Therapeutics (GALT), Albireo Pharma (ALBO) and NuCana (NCNA).
What other stocks do shareholders of Otonomy own?
Who are Otonomy's key executives?
Otonomy's management team includes the folowing people:
- Dr. Jay B. Lichter, Co-Founder & Chairman (Age 57)
- Dr. David Allen Weber, Pres, CEO & Director (Age 59)
- Mr. Paul E. Cayer, Chief Financial & Bus. Officer (Age 57)
- Mr. Robert Michael Savel II, Chief Technical Officer (Age 51)
- Dr. Allen F. Ryan Ph.D., Co-Founder and Member of the Advisory Panel
How do I buy shares of Otonomy?
Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Otonomy's stock price today?
One share of OTIC stock can currently be purchased for approximately $2.23.
How big of a company is Otonomy?
Otonomy has a market capitalization of $68.57 million and generates $750,000.00 in revenue each year. The biopharmaceutical company earns $-50,370,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Otonomy employs 49 workers across the globe.View Additional Information About Otonomy.
What is Otonomy's official website?
How can I contact Otonomy?
Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]
MarketBeat Community Rating for Otonomy (NASDAQ OTIC)
MarketBeat's community ratings are surveys of what our community members think about Otonomy and other stocks. Vote "Outperform" if you believe OTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OTIC will underperform the S&P 500 over the long term. You may vote once every thirty days.
